Xencor, Inc. (XNCR)

Market Cap	1.47B
Revenue (ttm)	133.62M
Net Income (ttm)	-177.37M
Shares Out	69.93M
EPS (ttm)	-2.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262,934
Open	21.59
Previous Close	21.78
Day's Range	20.82 - 21.59
52-Week Range	15.31 - 26.84
Beta	0.67
Analysts	Strong Buy
Price Target	35.00 (+66.03%)
Earnings Date	Nov 5, 2024

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 3, 2013
• Employees: 280
• Stock Exchange: NASDAQ
• Ticker Symbol: XNCR
• Website: https://www.xencor.com

Financial Performance

In 2023, Xencor's revenue was $168.34 million, an increase of 2.28% compared to the previous year's $164.58 million. Losses were -$126.09 million, 128.5% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for XNCR stock is "Strong Buy." The 12-month stock price forecast is $35.0, which is an increase of 66.03% from the latest price.

Price Target

$35.0

(66.03% upside)

Analyst Consensus: Strong Buy